Hemogenyx Pharmaceuticals Plc (HEMO.L) Stock Price
£337.5 0.7%
to add to portfolio
AI Score

-
Alternative
3 -
Fundamental
1 -
Technical
6
Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.
Sign up to get access to more historical data and insights on Hemogenyx Pharmaceuticals Plc, AI stock picks, stock alerts and much more.
HEMO.L AI Stock Analysis
AI stock analysis for HEMO.L is missing at the moment.
Our AI stock analysis reviews financial data, technical analysis, and alternative data insights to project stock performance. For example, analyzing a company like Hemogenyx Pharmaceuticals Plc (HEMO.L) provides a clear summary of future projections. Gain the edge you need to make confident, data-driven investment decisions.
Sign up and become a member to get access to AI stock analysis.
Sign up
Hemogenyx Pharmaceuticals Plc (HEMO.L) Price Prediction
Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Hemogenyx Pharmaceuticals Plc (HEMO.L), currently trading at £337.5, will... Sign up to access price prediction.
Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.
About HEMO.L

-
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases.
-
Symbol
HEMO.L
-
Market
LSE
-
Industry
Biotechnology
-
Market Cap
11.8M
Similar Stocks
![]() |
Codexis 0I0X.L |
$3.98 3.5% |
3 |
![]() |
Oxford Nanopore Technologies plc ONT.L |
£129.3 0.5% |
4 |
![]() |
Sareum Holdings SAR.L |
£19.7 1% |
3 |
![]() |
Viridian Therapeutics 0K1R.L |
$17.56 0% |
5 |
![]() |
Avacta Group Plc AVCT.L |
£45.42 0.8% |
4 |
News
HEMO.L Alternative Data
Web Traffic
Hemogenyx Pharmaceuticals Plc receives an estimated 1159 monthly visitors to hemogenyx.com, which is down by -4.2% over the last month.
-
Web Traffic
1159
-
Change from Previous Month
4.2%
-
3 Month Change
23.6%
News Mentions
Hemogenyx Pharmaceuticals Plc was mentioned 0 times in the news yesterday.
-
News Mentions
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
Twitter Followers
Hemogenyx Pharmaceuticals Plc has 2,075 Twitter Followers on its main Twitter (also known as X) account, which is down by -0.1% over the last month.
-
Twitter Followers
2075
-
Daily Change
0%
-
1 Month Change
0.1%
-
3 Month Change
1.2%
Facebook Engagement
Hemogenyx Pharmaceuticals Plc has engaged 0 users via their Facebook Page over the last 7 days.
-
Facebook Engagement
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
Youtube Subscribers
Hemogenyx Pharmaceuticals Plc has 158 subscribers on its main Youtube channel.
-
Youtube Subscribers
158
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0.6%
LinkedIn Followers
466 are following Hemogenyx Pharmaceuticals Plc on LinkedIn, up by 2.6% over the last month.
-
LinkedIn Followers
466
-
Daily Change
0.4%
-
1 Month Change
2.6%
-
3 Month Change
7.6%
LinkedIn Employees
According to LinkedIn, Hemogenyx Pharmaceuticals Plc has 9 employees, down by -10% over the last month.
-
LinkedIn Employees
9
-
Daily Change
10%
-
1 Month Change
10%
-
3 Month Change
12.5%
HEMO.L Financials
HEMO.L Key Metrics
-
Total Revenue
£0
-
Net Income
-£1.4K
-
Earnings per Share
£0
-
Free cash flow
-£1.2K
-
EBITDA
-£1.3K
-
EBITDA Ratio
0
-
Total Assets
£6.1M
HEMO.L 2-year Revenue & Income
HEMO.L 2-year Free Cash Flow
HEMO.L Technicals
HEMO.L SMA
HEMO.L RSI
FAQ
What's the current price of Hemogenyx Pharmaceuticals Plc (HEMO.L) Stock?
The price of an Hemogenyx Pharmaceuticals Plc (HEMO.L) share is £337.5.
What's the market cap of Hemogenyx Pharmaceuticals Plc?
The current market cap of Hemogenyx Pharmaceuticals Plc is 11.8M.
Should I buy or sell HEMO.L?
Hemogenyx Pharmaceuticals Plc exhibits several negative alternative data signals, leading us to expect continued underperformance in the coming months. As a result, we maintain a negative outlook on this stock.
Is Hemogenyx Pharmaceuticals Plc a good investment?
Considering the fundamentals, technical analysis, and alternative data insights, it may not be the best time to invest in Hemogenyx Pharmaceuticals Plc stock. There are several bearish signals and market challenges that could negatively impact Hemogenyx Pharmaceuticals Plc's future performance, suggesting that caution should be exercised before making any investment decisions.
Is now a good time to buy Hemogenyx Pharmaceuticals Plc (HEMO.L) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, it may not be the best time to buy Hemogenyx Pharmaceuticals Plc stock right now, as the outlook appears bearish.
What are some stocks similar to Hemogenyx Pharmaceuticals Plc (HEMO.L) that investors often compare it to?
Hemogenyx Pharmaceuticals Plc (HEMO.L) is often compared to similar stocks such as Codexis, Oxford Nanopore Technologies plc, Sareum Holdings, Viridian Therapeutics and Avacta Group Plc.
What is the forecast for Hemogenyx Pharmaceuticals Plc's stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Hemogenyx Pharmaceuticals Plc's stock price to be around £308.9 in 2026. Starting from the current price of £337.5, this represents a 8.5% change in price, indicating a bearish outlook for the stock.
How to buy Hemogenyx Pharmaceuticals Plc (HEMO.L) Stock?
Hemogenyx Pharmaceuticals Plc stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Hemogenyx Pharmaceuticals Plc shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.